PARIS, France I July 07, 2025 I PulseSight Therapeutics SAS, an ophthalmology biotech company developing disruptive non-viral vectorized therapies with ...

VIENNA, Austria / BERLIN, Germany I July 7, 2025 I HeartBeat.bio AG and biotx.ai GmbH today announced astrategic partnership to identify and validate ...

TOKYO, Japan I July 7, 2025 I Chugai Pharmaceutical Co., Ltd. (TOKYO: 4519, hereafter “Chugai”), and Gero PTE. LTD. (hereafter “Gero”), a Singapore-based ...

SHANGHAI, China I July 4, 2025 I Everest Medicines (HKEX: 1952.HK), a biopharmaceutical company focused on the discovery, clinical development, manufacturing ...

Approval based on NIAGARA Phase III trial results which showed a 32% reduction in the risk of recurrence and a 25% reduction in the risk of death for the ...

CINCINNATI, OH, USA I July 4, 2025 I During the COVID-19 pandemic, scientists learned that the critical path to infection started with the SARS-CoV-2 virus ...

BOSTON, MA, USA I July 4, 2025 I HotSpot Therapeutics, Inc., a biotechnology company pioneering the discovery and development of oral, small molecule ...

MONTREAL, Canada I July 02, 2025 I Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a commercial-stage ...

DURHAM, NC, USA and BEIJING, China I July 3, 2025 I Brii Biosciences Limited ("Brii Bio," stock code: 2137.HK), a biotechnology company developing ...

EMERYVILLE, CA, USA I July 02, 2025 I 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading late-stage biotechnology company advancing ...

BEIJING, China I July 03, 2025 I InnoCare Pharma (HKEX: 09969; SSE: 688428), a leading biopharmaceutical company focusing on the treatment of cancer and ...

EAST HANOVER, NJ, USA I July 3, 2025 I Novartis today announced top-line results from the Phase III GCAptAIN study evaluating Cosentyx® (secukinumab) in ...